Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Intellia Therapeutics (NTLA) Other Non-Current Assets: 2015-2024

Historic Other Non-Current Assets for Intellia Therapeutics (NTLA) over the last 8 years, with Dec 2024 value amounting to $3.8 million.

  • Intellia Therapeutics' Other Non-Current Assets fell 9.72% to $2.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $2.9 million, marking a year-over-year decrease of 9.72%. This contributed to the annual value of $3.8 million for FY2024, which is 16.16% down from last year.
  • According to the latest figures from FY2024, Intellia Therapeutics' Other Non-Current Assets is $3.8 million, which was down 16.16% from $4.5 million recorded in FY2023.
  • Intellia Therapeutics' 5-year Other Non-Current Assets high stood at $4.7 million for FY2020, and its period low was $3.8 million during FY2024.
  • In the last 2 years, Intellia Therapeutics' Other Non-Current Assets had a median value of $4.2 million in 2023 and averaged $4.2 million.
  • In the last 5 years, Intellia Therapeutics' Other Non-Current Assets soared by 62.60% in 2020 and then fell by 16.16% in 2024.
  • Intellia Therapeutics' Other Non-Current Assets (Yearly) stood at $4.7 million in 2020, then reached $4.5 million in 2023, then fell by 16.16% to $3.8 million in 2024.